PHARMACOECONOMIC COST-EFFECTIVENESS ANALYSIS OF PROVIDING MEDICAL CARE FOR PATIENTS WITH ARTERIAL HYPERTENSION
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2020.2.11189Keywords:
arterial hypertension, cost of drug therapy, antihypertensive drugsAbstract
Summary. Arterial hypertension is one of the cardiovascular diseases that has important medical and social significance. 7.7 million new cases are diagnosed each year, and the annual cost of the health care system to combat the causes and consequences of the disease, improve existing ones and the search for new methods of diagnosis and treatment is measured in billions.
The aim of the study – analysis of the patient's clinical histories with arterial hypertension in the context of 2010 and 2019 to compare and study the assistance level and work optimization.
Materials and Methods. Retrospective analysis of the patients clinical histories of 95 patients during 2010 and 84 patients during 2019 who were hospitalized at the Therapeutic Department of the Hospital No. 3, Тernopil with arterial hypertension.
Results. As a result of the study, it was found that among the examined patients in 2010 there were 46 men (48.42 %) and 49 women (51.57 %). The age of patients ranged from 20 to 77 years. During 2019, there were 54 (64.3 %) men and 30 (35.7 %) women, aged 23 to 83 years. As a result of the analysis of "Cost Minimization", the cheapest drugs in their group were found in 2010 and 2019. It was found that the total cost of arterial hypertension treatment for one patient in the hospital was – 255.09 UAH ($ 32) in 2010; and – UAH 3.820.15 ($ 144.26) in 2019 for the course of treatment.
Conclusions. In the structure of the cost of medical care for patients with hypertension in the therapeutic department, the most significant are the costs of purchasing drugs and hospital stay of patients. The presence of complications of the underlying disease significantly increases the cost of drugs. Pharmacoeconomic criteria were not taken into account when making decisions on the appointment of antihypertensive drugs.
References
Dyachenko LO, Manojlenko TS, Revenko IL, Doroxina GM, Gandzyuk VA, Byelyayeva TV. Current health problems and their minimization in the context of the armed conflict in Ukraine. [Актуальні проблеми здоров’я та мінімізація їх в умовах збройного конфлікту в Україні] 2018. Ukrainian.
Stepurko TG, Semygina TV, Barska YuG, Zaxozha V, Xarchenko N. [Results of the general research]. Indeks zdorovia. 2018. Ukrainian.
Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21): 2761-88. DOI: 10.1161/CIRCULATIONAHA.107.183885 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.183885
Mancia G, Fagard R, Narkiewicz K.; ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. European Heart Journal. 2013;31(10):1925-38.
Vasan RS, Beiser A, Seshadri S. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8): 1003-10. DOI: https://doi.org/10.1001/jama.287.8.1003
Flynn JT, Kaelber DC, Baker-Smith CM.; Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3): 1904. e20171904; DOI:10.1542/peds.2017-1904. DOI: https://doi.org/10.1542/peds.2017-1904
